0001415889-21-002991.txt : 20210614
0001415889-21-002991.hdr.sgml : 20210614
20210614164754
ACCESSION NUMBER: 0001415889-21-002991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210610
FILED AS OF DATE: 20210614
DATE AS OF CHANGE: 20210614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Xencor Inc
CENTRAL INDEX KEY: 0001326732
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38793
FILM NUMBER: 211015148
BUSINESS ADDRESS:
STREET 1: 111 WEST LEMON AVE
CITY: MONROVIA
STATE: CA
ZIP: 91016
BUSINESS PHONE: 626-305-5900
MAIL ADDRESS:
STREET 1: 111 WEST LEMON AVE
CITY: MONROVIA
STATE: CA
ZIP: 91016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inmune Bio, Inc.
CENTRAL INDEX KEY: 0001711754
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 475205835
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1200 PROSPECT STREET
STREET 2: SUITE 525
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 8589643720
MAIL ADDRESS:
STREET 1: 1200 PROSPECT STREET
STREET 2: SUITE 525
CITY: LA JOLLA
STATE: CA
ZIP: 92037
4
1
form4-06142021_010635.xml
X0306
4
2021-06-10
0001711754
Inmune Bio, Inc.
INMB
0001326732
Xencor Inc
111 W. LEMON AVE
MONROVIA
CA
91016
false
false
true
false
Common Stock
2021-06-10
4
J
0
192532
17.14
A
1777532
D
On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.
/s/ John J. Kuch
2021-06-14